GBP510

GBP510
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration
Intramuscular

GBP510 is a COVID-19 vaccine candidate developed by SK Bioscience and GSK.[1][2][3][4][5]

It was originally developed by the Institute for Protein Design of the University of Washington.[6][7]

The phase III clinical trial involves 4,037 participants. Should the trial confirm GBP510's efficacy and safety, the vaccine is expected to be approved in the first half of 2022.[8][9][10][11]

A booster dose trial is being planned. The booster is to be given 6 months after the second dose is administered.[11]

References

  1. ^ "SK COVID-19 Vaccine "GBP510" CEPI "Wave2" (next-generation vaccine)ed as the first development support target". SK Bioscience. 10 December 2020. Retrieved 28 July 2021.
  2. ^ "CEPI and SK bioscience extend collaboration to develop 'next generation' COVID-19 vaccine". Coalition for Epidemic Preparedness Innovations. 9 December 2020. Retrieved 28 July 2021.
  3. ^ "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)". ClinicalTrials.gov. 11 February 2021. NCT04750343. Retrieved 22 April 2021.
  4. ^ "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)". ClinicalTrials.gov. 8 February 2021. NCT04742738. Retrieved 22 April 2021.
  5. ^ Moon-hee C (11 June 2021). "SK Bioscience's COVID-19 Vaccine Uses Nanoparticle Technology of University of Washington". Business Korea. Retrieved 28 July 2021.
  6. ^ "Two nanoparticle vaccines enter clinical trials – Institute for Protein Design". Retrieved 18 August 2021.
  7. ^ "CEPI funds Phase 3 trial of UW Medicine COVID-19 vaccine". 24 May 2021.
  8. ^ "SK Bioscience advances first South Korean-developed COVID-19 vaccine to late-stage testing".
  9. ^ "SK Bioscience Starts to Administer COVID-19 Vaccines to Subjects in Phase 3 Trial". 31 August 2021.
  10. ^ SK Bioscience Co., Ltd. (14 October 2021). "A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older". International Vaccine Institute, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations. {{cite journal}}: Cite journal requires |journal= (help)
  11. ^ a b "IVI and SK bioscience Complete Recruitment for Phase III Clinical Trial of SKBS' COVID-19 Vaccine". Retrieved 7 February 2022.


Media files used on this page

Coronavirus. SARS-CoV-2.png
Author/Creator: Alexey Solodovnikov (Idea, Producer, CG, Editor), Valeria Arkhipova (Scientific Сonsultant), Licence: CC BY-SA 4.0
Scientifically accurate atomic model of the external structure of the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), a strain (genetic variant) of the coronavirus that caused Coronavirus disease (COVID-19), first identified in Wuhan, China, during December 2019

Each separate locus (amorphous blob) is an atom of:

  cobalt: membrane
  crimson: E protein
  green: M protein
  orange: glucose (glycan)
  turquoise : S (spike) glycoprotein
SARS-CoV-2 (Wikimedia colors).svg
Author/Creator: Geraki, Licence: CC BY-SA 4.0
SARS-CoV-2 logo in Wikimedia colors
Scholia logo.svg
Author/Creator: Lars Willighagen, Licence: CC BY-SA 4.0
SVG remake of proposal for Scholia logo (File:Scholia logo.png by User:Theklan).
WHO Rod.svg
The rod of Asclepius as depicted in the WHO logo.
Sida-aids.png
Author/Creator: User:FoeNyx © 2004 (artistic illustration), Licence: CC-BY-SA-3.0
VIH - HIV / SIDA - AIDS viruses.
SARS-CoV-2 (CDC-23312).png
This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by the 2019 Novel Coronavirus (2019-nCoV). Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically. This virus was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.
Syringe with Green Fluid.jpg
Author/Creator: Andres Rueda, Licence: CC BY 2.0
The following is the author's description of the photograph quoted directly from the photograph's Flickr page.
"Just wanted to test something with my ink refiller syringe. Filled with a oral-b mouthwash to give the greenish-blueish Max Payne valkyr effect. "